Oncolytics Biotech
ONCY
61 hedge funds and large institutions have $2.45M invested in Oncolytics Biotech in 2025 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 7 closing their positions.
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
9% more funds holding
Funds holding: 56 → 61 (+5)
0.02% less ownership
Funds ownership: 2.81% → 2.79% (-0.02%)
35% less capital invested
Capital invested by funds: $3.77M → $2.45M (-$1.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$162K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$85K |
| 3 |
VF
Virtu Financial
New York
|
+$84.2K |
| 4 |
TAM
Tocqueville Asset Management
New York
|
+$77.8K |
| 5 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$535K |
| 2 |
QC
Quadrature Capital
London,
United Kingdom
|
-$146K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$66.8K |
| 4 |
Goldman Sachs
New York
|
-$41.9K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$35K |
ONCY Hedge Fund Activity: Q4 2025 in Review
61 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q4 2025, worth a combined $2.45M — down 35% from $3.77M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ONCY positions and 7 closed out — a net gain of 6 holders — while 9 added to existing stakes and 5 trimmed.
The largest buyer was Connective Capital Management, opening a new position worth an estimated $162K. The largest seller was Citadel Advisors, exiting entirely with an estimated $535K sold.
- 61 institutional investors held Oncolytics Biotech (ONCY) as of Q4 2025, up from 56 in Q3 2025.
- Funds reported $2.45M of Oncolytics Biotech stock for Q4 2025, down 35% quarter-over-quarter.
- 13 funds opened new Oncolytics Biotech positions in Q4 2025 and 7 closed out, a net change of +6 holders.
- The largest Oncolytics Biotech buyer in Q4 2025 was Connective Capital Management, an estimated $162K added.
- The largest Oncolytics Biotech seller in Q4 2025 was Citadel Advisors, an estimated $535K sold.
Based on aggregated 13F filings for Q4 2025.